title: The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions.
abstract: Omega-3 (omega3) fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against cardiovascular disease. Despite these benefits, concern remains that omega3 fatty acids may increase lipid peroxidation. It has previously been shown that urinary F(2)-isoprostanes (F(2)-IsoPs) were reduced following omega3 fatty acid supplementation in humans. It is now determined whether EPA or DHA supplementation affects plasma F(2)-IsoPs. In two 6-week placebo-controlled interventions, Study A: overweight, dyslipidaemic men; and Study B: treated-hypertensive Type 2 diabetic, patients were randomized to 4 g daily EPA, DHA. Post-intervention plasma F(2)-IsoPs were significantly reduced by EPA (24% in Study A, 19% in Study B) and by DHA (14% in Study A, 23% in Study B) relative to the olive oil group. The fall in plasma F(2)-IsoPs was not altered in analyses that corrected for changes in plasma arachidonic acid, which was reduced with EPA and DHA supplementation. Neither F(3)- nor F(4)-IsoPs were observed in plasma in both studies. These results show that in humans, EPA and DHA reduce in vivo oxidant stress as measured in human plasma and urine.
authors.affiliation: University of Western Australia, Perth, WA, Australia. emilie.mas@uwa.edu.au
authors.forename: Emilie
authors.initials: E
authors.lastname: Mas
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Woodman
authors.forename: Valerie
authors.initials: V
authors.lastname: Burke
authors.forename: Ian B
authors.initials: IB
authors.lastname: Puddey
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Beilin
authors.forename: Thierry
authors.initials: T
authors.lastname: Durand
authors.forename: Trevor A
authors.initials: TA
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000178:diet therapy; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D028441:F2-Isoprostanes / Q000097:blood*; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000178:diet therapy; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause / Q000097:blood / Q000187:drug effects; D055815:Young Adult
chemical_list: D028441:F2-Isoprostanes; D015525:Fatty Acids, Omega-3; D010919:Placebos; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid